Japan · Delayed Price · Currency is JPY Sundrug Statistics
Total Valuation
Sundrug has a market cap or net worth of JPY 424.30 billion. The enterprise value is 401.99 billion.
| Market Cap | 424.30B |
| Enterprise Value | 401.99B |
Important Dates
The last earnings date was Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
Sundrug has 116.98 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | 116.98M |
| Shares Outstanding | 116.98M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 4.61% |
| Owned by Institutions (%) | 24.95% |
| Float | 67.82M |
Valuation Ratios
The trailing PE ratio is 13.52 and the forward PE ratio is 12.58. Sundrug's PEG ratio is 1.55.
| PE Ratio | 13.52 |
| Forward PE | 12.58 |
| PS Ratio | 0.50 |
| PB Ratio | 1.48 |
| P/TBV Ratio | 1.53 |
| P/FCF Ratio | 32.74 |
| P/OCF Ratio | 9.80 |
| PEG Ratio | 1.55 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.25, with an EV/FCF ratio of 31.02.
| EV / Earnings | 12.81 |
| EV / Sales | 0.48 |
| EV / EBITDA | 6.25 |
| EV / EBIT | 8.82 |
| EV / FCF | 31.02 |
Financial Position
The company has a current ratio of 1.78, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.78 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 0.74 |
| Debt / FCF | 3.72 |
| Interest Coverage | 121.96 |
Financial Efficiency
Return on equity (ROE) is 11.30% and return on invested capital (ROIC) is 12.31%.
| Return on Equity (ROE) | 11.30% |
| Return on Assets (ROA) | 6.37% |
| Return on Invested Capital (ROIC) | 12.31% |
| Return on Capital Employed (ROCE) | 13.72% |
| Weighted Average Cost of Capital (WACC) | 4.44% |
| Revenue Per Employee | 117.92M |
| Profits Per Employee | 4.39M |
| Employee Count | 7,145 |
| Asset Turnover | 1.83 |
| Inventory Turnover | 5.99 |
Taxes
In the past 12 months, Sundrug has paid 14.41 billion in taxes.
| Income Tax | 14.41B |
| Effective Tax Rate | 31.46% |
Stock Price Statistics
The stock price has decreased by -20.30% in the last 52 weeks. The beta is 0.12, so Sundrug's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | -20.30% |
| 50-Day Moving Average | 3,828.60 |
| 200-Day Moving Average | 4,202.96 |
| Relative Strength Index (RSI) | 34.77 |
| Average Volume (20 Days) | 468,960 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sundrug had revenue of JPY 842.51 billion and earned 31.39 billion in profits. Earnings per share was 268.36.
| Revenue | 842.51B |
| Gross Profit | 216.17B |
| Operating Income | 46.83B |
| Pretax Income | 45.80B |
| Net Income | 31.39B |
| EBITDA | 65.59B |
| EBIT | 46.83B |
| Earnings Per Share (EPS) | 268.36 |
Balance Sheet
The company has 70.52 billion in cash and 48.22 billion in debt, with a net cash position of 22.31 billion or 190.69 per share.
| Cash & Cash Equivalents | 70.52B |
| Total Debt | 48.22B |
| Net Cash | 22.31B |
| Net Cash Per Share | 190.69 |
| Equity (Book Value) | 286.00B |
| Book Value Per Share | 2,444.81 |
| Working Capital | 104.03B |
Cash Flow
In the last 12 months, operating cash flow was 43.30 billion and capital expenditures -30.34 billion, giving a free cash flow of 12.96 billion.
| Operating Cash Flow | 43.30B |
| Capital Expenditures | -30.34B |
| Depreciation & Amortization | 18.76B |
| Net Borrowing | 9.55B |
| Free Cash Flow | 12.96B |
| FCF Per Share | 110.79 |
Margins
Gross margin is 25.66%, with operating and profit margins of 5.56% and 3.73%.
| Gross Margin | 25.66% |
| Operating Margin | 5.56% |
| Pretax Margin | 5.44% |
| Profit Margin | 3.73% |
| EBITDA Margin | 7.79% |
| EBIT Margin | 5.56% |
| FCF Margin | 1.54% |
Dividends & Yields
This stock pays an annual dividend of 132.00, which amounts to a dividend yield of 3.58%.
| Dividend Per Share | 132.00 |
| Dividend Yield | 3.58% |
| Dividend Growth (YoY) | 0.77% |
| Years of Dividend Growth | 7 |
| Payout Ratio | 48.43% |
| Buyback Yield | -0.01% |
| Shareholder Yield | 3.62% |
| Earnings Yield | 7.40% |
| FCF Yield | 3.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Sundrug is 4,851.43, which is 33.76% higher than the current price. The consensus rating is "Buy".
| Price Target | 4,851.43 |
| Price Target Difference | 33.76% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on March 29, 2017. It was a forward split with a ratio of 2.
| Last Split Date | Mar 29, 2017 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Sundrug has an Altman Z-Score of 4.8 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.8 |
| Piotroski F-Score | 6 |